glp3.wiki

Methodology & Sourcing

Sources

The reference uses primary sources: peer-reviewed journals (NEJM, Lancet, JAMA), clinical trial registries (ClinicalTrials.gov), and FDA / EMA regulatory filings. Eli Lilly and Novo Nordisk investor disclosures are treated as primary for their own trial readouts. Readers should be able to trace numerical claims to a source and identify the study population, endpoint and duration.

What each source can establish

  • Regulatory documents establish the status and conditions of the named product or process.
  • Peer-reviewed trial papers provide methods, populations, analyses and limitations to assess alongside the result.
  • Trial registries describe registered designs and recruitment. A completed study without posted results does not establish an outcome.
  • Sponsor announcements are primary accounts of what the company reported. A topline release is not the same as a full peer-reviewed paper.
  • Videos and personal reports are sources for what someone said or experienced, not controlled evidence that a treatment caused the outcome.

Fact-checking

Fact-checks compare a claim with the evidence available for that specific question. When we review a YouTube video or public claim, we quote the specific statement and cross-reference it against the relevant trial data.

Updates

Articles show an editorial update date near the title. Source dates describe when the underlying evidence was published; they can be older. Substantive corrections and new evidence warrant an update, while a routine visit does not make an old finding new. Live trial listings show the registry record’s update date separately.

Not medical advice

Retatrutide is investigational and not FDA-approved. Nothing on this site is a substitute for a conversation with a licensed clinician. See the disclaimer for full terms.

Corrections

Send a page URL, the disputed statement and a supporting source to glp3@jkyf.dev or use the correction form. Corrections should identify what changed and preserve the distinction between evidence, interpretation and uncertainty.